PharmaCyte Biotech, Inc. PMCB
NASDAQ
| 07/31/2026 | 04/30/2026 | 01/31/2026 | 10/31/2025 | 07/31/2025 | |
|---|---|---|---|---|---|
| Revenue | -- | -- | -- | -- | -- |
| Total Other Revenue | -- | -- | -- | -- | -- |
| Total Revenue | -- | -- | -- | -- | -- |
| Cost of Revenue | -- | -- | -- | -- | -- |
| Gross Profit | -- | -- | -- | -- | -- |
| SG&A Expenses | 25.71% | -1.66% | 140.47% | 22.35% | -35.79% |
| Depreciation & Amortization | -- | -- | -- | -- | -- |
| Other Operating Expenses | -- | -- | -- | -- | -- |
| Total Operating Expenses | 18.67% | -7.69% | 120.57% | 24.32% | -33.15% |
| Operating Income | -18.67% | 7.69% | -120.57% | -24.32% | 33.15% |
| Income Before Tax | 39.22% | -137.39% | 124.53% | -404.76% | -135.69% |
| Income Tax Expenses | -- | -- | -- | -- | -- |
| Earnings from Continuing Operations | 39.22% | -137.39% | 124.53% | -404.76% | -135.69% |
| Earnings from Discontinued Operations | -- | -- | -- | -- | -- |
| Extraordinary Item & Accounting Change | -- | -- | -- | -- | -- |
| Minority Interest in Earnings | -- | -- | -- | -- | -- |
| Net Income | 39.22% | -137.39% | 124.53% | -404.76% | -135.69% |
| EBIT | -18.67% | 7.69% | -120.57% | -24.32% | 33.15% |
| EBITDA | -- | -- | -- | -- | -- |
| EPS Basic | 56.19% | -128.89% | 61.60% | -485.03% | -156.34% |
| Normalized Basic EPS | 107.29% | -86.16% | -634.62% | -272.47% | -581.82% |
| EPS Diluted | 56.19% | -128.89% | 61.60% | -485.03% | -156.34% |
| Normalized Diluted EPS | 107.29% | -86.16% | -634.62% | -272.47% | -581.82% |
| Average Basic Shares Outstanding | 57.97% | 55.49% | 33.09% | -11.01% | -13.61% |
| Average Diluted Shares Outstanding | 57.97% | 55.49% | 33.09% | -11.01% | -13.61% |
| Dividend Per Share | -- | -- | -- | -- | -- |
| Payout Ratio | -- | -- | -- | -- | -- |